Table 3 List of immunomodulatory antibodies currently in clinical development and their respective isotypes
From: The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer
Antibody | Target | Company | Latest active clinical phase | Isotype |
|---|---|---|---|---|
Ipilimumab | CTLA-4 | BMS | Approved | IgG1 |
Tremelimumab | CTLA-4 | MedImmune/AstraZeneca | II | IgG2 |
Nivolumab | PD-1 | BMS | Approved | IgG4 |
MK-3475 | PD-1 | Merck | III | IgG4 |
CT-011 | PD-1 | CureTech | II | IgG1 |
MPDL3280A | PD-L1 | Genentech/Roche | III | Aglycosyl IgG1 |
MEDI4736 | PD-L1 | MedImmune/AstraZeneca | I | IgG1 TM |
MDX-1105 | PD-L1 | BMS | I | IgG4 |
MSB0010718C | PD-L1 | Merck KGaA | I | IgG1 |
BMS-663513 | CD137 | BMS | I | IgG4 |
PF-05082566 | CD137 | Pfizer | I | IgG2 |
TRX518 | GITR | GITR Inc | I | Aglycosyl IgG1 |
MEDI6469 | OX40 | MedImmune/AstraZeneca/AgonOX | I | Mouse IgG1 |
CP-870,893 | CD40 | Roche | I | IgG2 |
CDX-1127 | CD27 | CellDex | I | IgG1 |
Lirilumab; IPH2102 | KIR | BMS/Innate Pharma | II | IgG4 |
MGA271 | B7-H3 | Macrogenics/Servier | I | IgG1 |
Alemtuzumab | CD52 | Genzyme/Bayer | Approved | IgG1 |